- Published on
Infectious Disease and Microbiology – Creutzfeldt–Jakob Disease
Creutzfeldt–Jakob disease (CJD) is a transmissible spongiform encephalopathy, a group of chronic, progressive, and invariably fatal neurodegenerative disorders affecting humans and animals. Animal forms include scrapie in sheep and bovine spongiform encephalopathy (BSE) in cattle. Human prion diseases include CJD, kuru, Gerstmann–Sträussler–Scheinker syndrome, and fatal familial insomnia. CJD is the most common human prion disease and is characterized by rapidly progressive dementia, myoclonus, and motor dysfunction. It occurs in sporadic, familial, iatrogenic, and variant forms, with sporadic CJD (sCJD) accounting for approximately 85% of cases.
The incidence of sporadic CJD is about 1 case per million people per year, typically affecting individuals between 50 and 60 years of age. Familial cases follow an autosomal dominant inheritance pattern and are linked to mutations in the PRNP gene. Higher frequencies of familial CJD have been reported in certain regions, including North Africa, the Middle East, Italy, and Slovakia. Iatrogenic transmission has occurred through corneal transplantation, dural grafts, contaminated neurosurgical instruments, stereotactic electrodes, and cadaveric human growth hormone or gonadotropin therapy. Variant CJD (vCJD), first identified in 1996 during the BSE outbreak in the United Kingdom, represents animal-to-human transmission. A small number of cases have been documented in the United States.
The pathophysiology involves accumulation of abnormal misfolded prion protein (PrPSc), derived from the normal cellular prion protein encoded by PRNP. These abnormal proteins aggregate in neuronal tissue, leading to neuronal loss, gliosis, and the characteristic spongiform changes—small vacuoles within the neuropil. Inflammation is notably absent. Pathologic changes are most prominent in the cerebral cortex but may also involve basal ganglia, cerebellum, and thalamus. Prion plaques and rods on electron microscopy are pathognomonic.
Clinically, CJD presents with rapidly progressive dementia, myoclonus (present in more than 90% of patients), pyramidal and extrapyramidal signs, and cerebellar dysfunction. Early features include cognitive slowing, impaired concentration, memory loss, mood changes, emotional lability, and hallucinations. As the disease progresses, patients may develop tremor, choreoathetosis, rigidity, hypokinesia, hyperreflexia, spasticity, and extensor plantar responses. Autonomic and endocrine disturbances may occur in certain prion syndromes such as fatal familial insomnia.
Variant CJD typically affects younger patients (19–41 years) and presents initially with behavioral and psychiatric symptoms, followed by ataxia, myoclonus, and dementia. Disease progression leads to death within 7–23 months. Kuru, historically described in Papua New Guinea, is characterized by tremors, ataxia, and later dementia, with incubation periods that may extend up to 50 years.
Definitive diagnosis requires histopathologic examination of brain tissue. Cerebrospinal fluid (CSF) is typically unremarkable, though mild protein elevation may occur. Detection of 14-3-3 protein in CSF may support the diagnosis, but sensitivity and specificity range from 60–90%, and elevations can occur in other neurologic disorders. Genetic testing can identify PRNP mutations in familial cases. Serum S100 protein levels may be elevated. EEG in sporadic CJD often shows periodic sharp-wave complexes, with sensitivity around 64% and specificity 91%, though this pattern is not typical in variant or familial forms. MRI may reveal hyperintense signals in the striatum or other deep brain structures, often disproportionate to visible cortical atrophy. In variant CJD, periodic EEG findings are usually absent.
The differential diagnosis of rapidly progressive dementia with myoclonus includes Alzheimer disease, frontotemporal dementia, Lewy body dementia, HIV-associated dementia, neurosyphilis, tuberculous meningitis, Whipple disease, progressive multifocal leukoencephalopathy, lymphoma, metabolic disorders, autoimmune encephalitis, and paraneoplastic syndromes.
There is currently no effective treatment. CJD is uniformly fatal. Various agents, including amantadine, flupirtine, chlorpromazine, and other experimental therapies targeting prion protein aggregation, have been studied without demonstrated survival benefit. Management is supportive.
Preventive measures in the United States include strict regulations to prevent BSE introduction, control of high-risk bovine materials in the food supply, and adherence to infection control guidelines in medical procedures. The overall risk of transmission is considered minimal under current public health measures.
Prognosis is poor, with progressive neurologic decline leading to death, often within one year of symptom onset in sporadic cases. Serial imaging may demonstrate rapid brain atrophy and ventricular enlargement as the disease advances.
- Published on
Infectious Disease and Microbiology – Dengue
Dengue is a mosquito-borne viral illness that causes a severe flu-like disease and, in some cases, progresses to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), with a fatality rate of approximately 1–5% in severe cases. It is caused by the dengue virus, a single-stranded RNA virus of the Flaviviridae family, with four antigenically distinct serotypes (types 1–4). Humans and nonhuman primates serve as reservoirs. Transmission occurs through the bite of infected Aedes aegypti and Aedes albopictus, which are predominantly day-biting mosquitoes.
Globally, about 2.5 billion people—nearly two-fifths of the world’s population—are at risk of infection. An estimated 50–100 million infections occur annually, including approximately 500,000 cases of DHF and hundreds of thousands of deaths worldwide. Transmission increases during the rainy season due to mosquito breeding in stagnant water. Dengue is endemic in around 100 countries across Asia, the Pacific, the Americas, Africa, and the Caribbean, primarily in tropical and subtropical urban and suburban areas.
The principal risk factor is travel to or residence in endemic regions. No genetic predisposition has been clearly identified. Prevention focuses on avoiding mosquito bites and vector control. Measures include using insect repellents containing at least 30% DEET, wearing long-sleeved clothing (preferably treated with permethrin), and eliminating mosquito breeding sites such as stagnant water. Indoor insecticide use and larvicidal agents may reduce mosquito populations. Bed nets are of limited value because Aedes mosquitoes bite during the daytime.
After inoculation, the incubation period ranges from 3 to 14 days, most commonly 4–7 days. The virus initially replicates in dendritic cells and then spreads to reticuloendothelial cells, hepatocytes, and endothelial cells. Immune mediators contribute to the acute febrile illness, which typically lasts 5–7 days, with full recovery within 7–10 days in uncomplicated cases. Prior infection with a different serotype increases the risk of DHF and DSS due to immune-mediated mechanisms.
DHF and DSS usually develop between days 3 and 7 of illness, often at the end of the febrile phase. Increased capillary permeability leads to plasma leakage, hemoconcentration, pleural effusions, and ascites. Thrombocytopenia, capillary fragility, and disseminated intravascular coagulation (DIC) can result in hemorrhage ranging from petechiae to life-threatening gastrointestinal bleeding. Liver involvement may cause hepatitis and coagulopathy, which can be fatal in severe cases. Mother-to-child transmission has been documented.
Clinically, patients present with fever, headache, chills, myalgias, bone pain, rash, nausea, vomiting, abdominal pain, and anorexia. Cutaneous hyperesthesia and changes in taste may occur. Hemorrhagic manifestations include bruising, epistaxis, gum bleeding, menorrhagia, and gastrointestinal bleeding. A careful travel history is essential.
On physical examination, fever is common. Rash may appear in two phases: an initial generalized blanching macular rash followed by a morbilliform maculopapular rash that typically spares the palms and soles. Conjunctival and pharyngeal injection are frequent findings. Signs of shock—tachycardia, hypotension, and delayed capillary refill—indicate severe disease. Hepatomegaly, lymphadenopathy, mucosal bleeding, and altered mental status (suggesting encephalopathy or intracranial hemorrhage) may also be present.
Laboratory evaluation often reveals leukopenia, lymphopenia, elevated hematocrit (reflecting hemoconcentration), and thrombocytopenia. Liver transaminases are commonly elevated, and albumin may be low. Electrolyte disturbances such as hyponatremia and metabolic acidosis may occur. Coagulation studies may show prolonged PT and APTT, low fibrinogen, and elevated fibrin degradation products in DIC. Serologic testing (ELISA for IgM and IgG) is commonly used for diagnosis. Imaging may demonstrate pleural or pericardial effusions and ascites. Head CT is indicated in patients with altered consciousness.
The differential diagnosis includes malaria, yellow fever, rickettsial infections, leptospirosis, typhoid fever, viral hepatitis, meningitis, bacterial sepsis, and other viral illnesses such as influenza or chikungunya.
There is no specific antiviral treatment for dengue, DHF, or DSS. Management is supportive. Aspirin and nonsteroidal anti-inflammatory drugs should be avoided due to bleeding risk. Adequate analgesia, antipyretics (such as acetaminophen), and careful fluid management are essential. In severe cases, aggressive fluid resuscitation using isotonic crystalloids or colloids is required to maintain adequate blood pressure and organ perfusion. Advanced life support protocols should be followed in patients with shock. Blood products may be necessary in cases of severe hemorrhage. Close monitoring of fluid balance, urine output, electrolytes, and coagulation status is critical.
Hospital admission is indicated for patients with hemodynamic instability, DHF, DSS, or significant bleeding. Intensive care is required for hypotension, DIC, or organ failure. Discharge is appropriate once the patient is hemodynamically stable and has recovered clinically.
Prognosis is generally excellent for uncomplicated dengue fever, with most patients recovering fully. Those who survive the critical phase of DHF or DSS usually recover without long-term sequelae. However, complications may include neurological manifestations (encephalopathy, seizures, Guillain–Barré syndrome, transverse myelitis), myocarditis, and liver failure. Cases should be reported to public health authorities, and patients should be informed that infection with a different serotype in the future increases the risk of severe disease.
- Published on
Infectious Disease and Microbiology – Cytomegalovirus Infection
Cytomegalovirus (CMV) infection refers to a spectrum of diseases caused by Cytomegalovirus, a DNA virus belonging to the herpesvirus family (Human Herpesvirus 5). Like other herpesviruses, CMV establishes lifelong latency after primary infection and may reactivate during periods of immunosuppression. Infection may be asymptomatic, present as a mononucleosis-like syndrome, or cause severe tissue-invasive disease, particularly in immunocompromised individuals.
CMV is a common pathogen worldwide. In the United States, the incidence among individuals aged 10–49 years is approximately 1.6 infections per 100 susceptible persons per year. About 27,000 new infections occur annually among seronegative pregnant women. Seroprevalence increases with age and is higher among individuals of lower socioeconomic status. Approximately 60% of people older than 6 years in the US are seropositive, and rates exceed 90% in individuals over 80 years of age.
Immunosuppression is the primary risk factor for severe CMV disease. In solid organ transplantation (SOT), the highest risk occurs when a CMV-seronegative recipient receives an organ from a CMV-seropositive donor (CMV D+/R– mismatch). In allogeneic hematopoietic stem cell transplantation, higher risk occurs when a CMV-seropositive recipient receives a graft from a seronegative donor (CMV D–/R+). Lung, small intestine, and pancreas transplant recipients are at particularly high risk, followed by liver and heart transplant recipients, while kidney recipients have lower risk. Additional risk factors include use of lymphocyte-depleting agents (e.g., anti-thymocyte globulin), acute allograft rejection, graft-versus-host disease, and HIV infection with CD4 counts below 50 cells/mm³. CMV is also associated with bone marrow transplantation, AIDS, and hematologic malignancies such as lymphoma and leukemia.
Pathophysiologically, primary infection in transplant recipients occurs through donor transmission (CMV D+/R–), while reactivation occurs when latent virus in a seropositive recipient becomes active during immunosuppression. CMV infection may be asymptomatic (subclinical infection) or symptomatic. Symptomatic infection is classified as CMV syndrome (fever and systemic symptoms without organ involvement) or tissue-invasive disease affecting specific organs. The transplanted organ is particularly vulnerable to tissue-invasive disease.
In immunocompetent individuals, CMV infection is often asymptomatic or presents as a mononucleosis-like illness with fever, malaise, myalgias, lymphadenopathy, splenomegaly, and sometimes rash. In immunosuppressed patients, CMV syndrome presents with fever, malaise, myalgias, and arthralgias. Tissue-invasive disease may involve multiple organs. CMV colitis is common and presents with abdominal pain and diarrhea. CMV gastritis may cause odynophagia, nausea, and vomiting. Pneumonitis presents with fever, cough, and dyspnea and is particularly severe in bone marrow transplant recipients. Hepatitis and myocarditis may occur. CMV retinitis, especially in advanced HIV infection, causes progressive visual loss and characteristic peripheral retinal lesions with yellow-white exudates and hemorrhage. Meningoencephalitis presents with headache, photophobia, and lethargy. Spinal cord involvement (myelitis or polyradiculitis) may cause back pain and ascending weakness, particularly in HIV-infected patients.
Laboratory findings may include anemia, thrombocytopenia, and atypical lymphocytosis. CMV IgG indicates prior exposure and latent infection; IgM may indicate acute infection or reactivation but is often unreliable in immunosuppressed individuals. Because of rapid turnaround time and high sensitivity, nucleic acid amplification testing (real-time PCR) and pp65 antigenemia assays are now preferred diagnostic tools. Antigenemia testing detects CMV pp65 protein in leukocytes but is less useful in neutropenic patients. Viral culture may demonstrate cytopathic effects after several weeks; shell vial assays provide results within 24–48 hours. Drug resistance should be suspected if viral load fails to decline after two weeks of full-dose therapy. Mutations in UL97 are associated with ganciclovir resistance, while UL54 mutations may confer cross-resistance to ganciclovir, foscarnet, and cidofovir.
Imaging findings depend on organ involvement. CMV pneumonitis shows interstitial infiltrates on chest imaging. CMV colitis may show bowel wall thickening on CT. Brain MRI in CMV encephalitis may demonstrate periventricular inflammation or meningeal enhancement. Tissue biopsy reveals characteristic cytopathic changes with large intranuclear inclusions surrounded by a clear halo (“owl’s eye” appearance), sometimes accompanied by cytoplasmic inclusions.
The differential diagnosis varies by presentation and includes infectious mononucleosis, toxoplasmosis, acute HIV infection, human herpesvirus 6 infection, viral hepatitis, viral gastroenteritis, cryptosporidiosis, and Clostridioides difficile infection.
In immunocompetent individuals, CMV syndrome is usually self-limited and does not require treatment. In immunocompromised patients, antiviral therapy is essential. First-line therapy is intravenous ganciclovir (5 mg/kg twice daily, dose-adjusted for renal function). Oral valganciclovir (900 mg twice daily) may be used for mild-to-moderate disease and as step-down therapy. For CMV retinitis in AIDS patients, systemic therapy combined with intraocular ganciclovir implant improves outcomes. Second-line agents for ganciclovir-resistant CMV include foscarnet and cidofovir. High-dose ganciclovir may be considered in low-level resistance. Reduction of immunosuppressive therapy is recommended when possible, and CMV immunoglobulin may be used in severe disease, particularly pneumonitis.
Patients receiving treatment should undergo weekly monitoring of viral load. Therapy typically continues for at least 2–4 weeks and preferably until viremia clears, with additional maintenance therapy in high-risk individuals. Prognosis varies with immune status; severe disease such as pneumonitis or encephalitis carries high mortality. CMV colitis may lead to perforation and peritonitis, myocarditis may cause heart failure, and in HIV-infected patients CMV may cause cauda equina syndrome. In transplant recipients, indirect CMV effects include acute rejection, chronic graft failure, bronchiolitis obliterans, accelerated vasculopathy, vanishing bile duct syndrome, and chronic kidney injury.
Congenital CMV infection is a major cause of congenital anomalies in industrialized countries and may result in fetal loss, neonatal jaundice, anemia, and central nervous system damage. There is currently no available CMV vaccine.
- Published on
Infectious Disease and Microbiology – Cystitis
Cystitis is a lower urinary tract infection (UTI) involving the bladder and occurs in both women and men. It is one of the most common bacterial infections encountered in clinical practice. In the United States, approximately 7 million cases of UTI occur annually. About one-third of women up to 24 years of age will experience at least one episode requiring antibiotic treatment. Furthermore, nearly half of women whose uncomplicated UTIs resolve spontaneously will develop a recurrence within one year. Cystitis is significantly more prevalent in young women than in young men (approximately 20% vs. 0.5% between ages 16–35 years).
Risk factors vary by population. In premenopausal women, risk factors include prior UTI, congenital urinary tract abnormalities, frequent or recent sexual activity, use of spermicides, diaphragm contraception, increasing parity, diabetes mellitus, pregnancy, obesity, neurologic disease, and conditions requiring indwelling or repetitive bladder catheterization. In postmenopausal women, vaginal atrophy, incomplete bladder emptying, pelvic organ prolapse (rectocele, cystocele, urethrocele, uterovaginal prolapse), diabetes, and prior UTIs increase risk. In men, prostatic hypertrophy, urethral obstruction, catheterization, urinary incontinence, and prior urologic surgery are important risk factors.
The most common etiologic agent is Escherichia coli, responsible for more than 80% of cases. Other Enterobacteriaceae include Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species, Citrobacter species, Serratia species, Salmonella species, and Morganella morganii. Non-Enterobacteriaceae such as Pseudomonas aeruginosa may also be involved, particularly in healthcare-associated infections. Among gram-positive organisms, Staphylococcus saprophyticus is a notable cause, especially in young sexually active women. The emergence of extended-spectrum β-lactamase (ESBL)-producing E. coli and other resistant uropathogens is a growing concern in both community and hospital settings.
Clinically, patients typically present with dysuria, urinary frequency, urgency, abrupt onset of symptoms, and sometimes turbid, foul-smelling, or bloody urine. Suprapubic tenderness may be present, and approximately 10% report low back discomfort. Children may present with nonspecific symptoms such as fever, vomiting, or diarrhea. Elderly patients often exhibit minimal or atypical symptoms.
Physical examination may reveal suprapubic tenderness but is otherwise often unremarkable. Diagnosis is supported by laboratory evaluation. Urinary dipstick testing may detect leukocyte esterase and nitrites. Urine microscopy can demonstrate pyuria and bacteriuria. Urine culture confirms the diagnosis and guides antimicrobial therapy. Pregnancy testing should be considered in women of childbearing age. Imaging is generally unnecessary in uncomplicated cases but ultrasonography may be indicated in men, in women who fail to respond to therapy, or in cases of recurrent infection not clearly related to sexual activity.
The differential diagnosis includes infectious conditions such as pyelonephritis (upper UTI), urethritis, vaginitis, and asymptomatic bacteriuria, as well as noninfectious causes including interstitial cystitis, urolithiasis, bladder tumor, and chronic prostatitis or chronic pelvic pain syndrome.
Acute uncomplicated cystitis is treated with short-course antimicrobial therapy. Common regimens include trimethoprim-sulfamethoxazole for three days, trimethoprim alone for three days, fluoroquinolones such as ciprofloxacin or levofloxacin for three days, fosfomycin as a single oral dose, or nitrofurantoin for five to seven days. Selection should be guided by local resistance patterns. In pregnancy, amoxicillin, nitrofurantoin (avoided near term due to risk of neonatal hemolysis), cefpodoxime, or fosfomycin may be used. Recurrent cystitis may be managed with continuous low-dose prophylaxis using agents such as trimethoprim, trimethoprim-sulfamethoxazole, nitrofurantoin, or fluoroquinolones, though this strategy must be individualized due to increasing antimicrobial resistance.
Complementary approaches have been studied. Certain probiotics (e.g., Lactobacillus strains) may reduce recurrence rates. Cranberry products have been suggested to reduce bacterial adherence and may modestly lower recurrence in women with recurrent UTIs. Methenamine salts may be beneficial in short-term prophylaxis in patients without structural urinary abnormalities. Phenazopyridine may relieve dysuria but does not treat infection and carries potential adverse effects such as hemolytic anemia.
The prognosis for acute uncomplicated cystitis is excellent with appropriate antibiotic therapy. However, recurrent episodes are common, especially in patients with underlying risk factors. Complications may include urethritis, progression to pyelonephritis, and psychological distress associated with recurrent infection. Preventive measures include good hygiene, avoidance of spermicides and diaphragms, careful monitoring during pregnancy, and glycemic control in patients with diabetes.
- Published on
Infectious Disease and Microbiology – Cysticercosis
Cysticercosis is a parasitic infection caused by the larval stage of the pork tapeworm, Taenia solium. Humans develop cysticercosis when they ingest tapeworm eggs, which hatch into larvae (oncospheres) that penetrate the intestinal wall and disseminate hematogenously to tissues. The larvae develop into cysticerci—fluid-filled cysts—within various organs. The central nervous system (CNS) is most commonly affected, a condition known as neurocysticercosis. Other commonly involved sites include skeletal muscle, subcutaneous tissue, heart, and eyes. Many infections remain asymptomatic, but symptomatic disease can result in significant neurologic morbidity.
Cysticercosis occurs worldwide and affects more than 50 million people. It is highly prevalent in Central and South America, sub-Saharan Africa, India, Southeast Asia, and parts of Eastern Europe. In endemic villages, 10% or more of the population may be seropositive, and up to 6% may harbor adult intestinal tapeworms at any time. Neurocysticercosis is the most common parasitic infection of the CNS and is the leading cause of seizures in many developing countries. In Mexico, for example, up to 10% of brain CT scans in some institutions show evidence of neurocysticercosis.
Risk factors include consumption of raw or undercooked pork, poor sanitation, close proximity to pigs (particularly where pigs have access to human feces), and inadequate hand hygiene leading to fecal–oral transmission. Humans are the definitive host for the adult intestinal worm, which resides in the small intestine and sheds eggs or gravid proglottids in stool. Pigs serve as intermediate hosts when they ingest eggs, allowing larvae to encyst in muscle tissue. Humans acquire intestinal tapeworm infection by eating undercooked pork containing cysticerci. In contrast, cysticercosis occurs when humans ingest eggs directly—either through contaminated food or water, poor hygiene, or autoinfection in individuals already infected with the adult worm.
In neurocysticercosis, neurologic symptoms primarily result from the inflammatory response that occurs when cysticerci degenerate. Mass effect may also occur when cysts obstruct cerebrospinal fluid flow, leading to hydrocephalus and increased intracranial pressure. Extraneural disease may involve the eyes (commonly vitreous humor or subretinal space), causing visual disturbance or chronic uveitis. Subcutaneous cysts present as firm nodules that may become inflamed. Skeletal muscle involvement is usually asymptomatic but may produce muscular pseudohypertrophy in heavy infestations. Cardiac involvement can lead to conduction abnormalities.
Clinical manifestations vary widely. Patients may present with chronic headache, seizures, focal neurologic deficits, altered mental status, nausea, vomiting, visual disturbances, insomnia, anorexia, or weight loss. Seizures are the most common presentation. Physical examination often reveals absence of fever, nonfocal neurologic findings, papilledema, hyperreflexia, or visual deficits. Intraocular larvae may be visualized on ophthalmoscopy. Subcutaneous nodules resembling sebaceous cysts may be palpable.
Diagnosis relies on imaging and serologic testing. Brain CT and MRI are key diagnostic tools; MRI is especially useful for detecting brainstem or ventricular cysts. Imaging may show viable cysts, ring-enhancing lesions, or calcified granulomas. Soft tissue radiographs may reveal calcified cysts in muscle. Serologic testing includes enzyme-linked immunoelectrotransfer blot (EITB), which has high sensitivity and specificity in patients with multiple cysts, though sensitivity is lower with single lesions. Stool examination may identify ova and parasites if intestinal infection is present. Lumbar puncture findings are nonspecific but may show lymphocytosis, elevated protein, and decreased glucose in cases with significant inflammation. Biopsy of subcutaneous nodules can confirm the diagnosis.
The differential diagnosis of neurocysticercosis includes brain abscess, neoplasms, tuberculosis, toxoplasmosis, encephalitis, stroke, intracranial hemorrhage, meningitis, and other causes of seizures or focal neurologic deficits.
Treatment includes antiparasitic therapy combined with anti-inflammatory management. First-line therapy consists of praziquantel for two weeks along with corticosteroids (prednisone or dexamethasone) to control inflammation. Albendazole is an effective alternative and is commonly used. Anticonvulsant therapy (e.g., phenytoin, phenobarbital, or benzodiazepines for acute seizures) is required for seizure control. Neurosurgical interventions, such as ventricular shunting or burr hole procedures, may be necessary for obstructive hydrocephalus or elevated intracranial pressure. Ophthalmologic or neurosurgical referral is indicated for ocular or severe CNS involvement.
Prognosis is generally excellent with appropriate diagnosis and treatment, although some patients require long-term anticonvulsant therapy due to persistent calcified lesions. Complications include status epilepticus, stroke, intracranial herniation, hydrocephalus requiring shunt placement, shunt-related complications, and permanent vision loss.
Prevention focuses on improved sanitation, hand hygiene, proper cooking of pork, freezing pork to kill cysticerci, strict meat inspection, treatment of infected individuals, and control of infection in pig populations. Education regarding seizure management and avoidance of high-risk activities after seizures is essential for affected patients.
- Published on
Infectious Disease and Microbiology – Conjunctivitis
Conjunctivitis is an inflammatory reaction of the conjunctiva characterized by hyperemia (red eye) and discharge. It may be acute or chronic and can be infectious or noninfectious. Important infectious forms include trachoma, caused by Chlamydia trachomatis serotypes A–C; inclusion conjunctivitis, caused by sexually transmitted C. trachomatis serotypes D–K; and ophthalmia neonatorum, an acute mucopurulent conjunctivitis occurring within the first month of life.
The incidence of infectious conjunctivitis in primary care settings is significant. In the Netherlands, rates as high as 13.9 cases per 1000 person-years have been reported. In the United States, Chlamydia species are the most common cause of ophthalmia neonatorum (approximately 6.2 per 1000 live births). The incidence of gonococcal ophthalmia neonatorum has decreased dramatically due to prophylaxis at birth. Trachoma remains a major cause of preventable blindness in parts of northern and sub-Saharan Africa, the Middle East, and Asia. Although global prevalence has declined with improved hygiene, millions worldwide remain visually impaired from trachoma.
Risk factors for trachoma include poverty, overcrowding, poor sanitation, and limited access to clean water and healthcare. Transmission occurs via direct contact (hands, towels) and flies. Viral conjunctivitis is often associated with upper respiratory infections or contact with infected individuals. Adult inclusion conjunctivitis may be associated with a history of urethritis, vaginitis, or cervicitis.
Bacterial conjunctivitis develops when normal ocular defense mechanisms are disrupted, such as in tear film abnormalities, ocular surface damage, or systemic immunosuppression. Infectious causes include bacteria (Staphylococcus, Streptococcus, Haemophilus, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, Bartonella henselae), viruses (adenovirus, enterovirus, HSV, VZV), fungi, and parasites. Viral conjunctivitis may present as epidemic keratoconjunctivitis (EKC), pharyngoconjunctival fever, acute hemorrhagic conjunctivitis, or in association with systemic viral illnesses.
Patients typically report tearing, mucous or mucopurulent discharge, eyelid swelling, redness, and foreign-body sensation. Pain is usually minimal and visual acuity only slightly reduced. Gonococcal conjunctivitis presents rapidly with profuse purulent discharge in sexually active adults or neonates. Viral EKC often begins in one eye and spreads to the other, with watery discharge and photophobia.
On examination, conjunctivitis presents with hyperemia, eyelid edema, and discharge. Viral and chlamydial conjunctivitis commonly show a follicular reaction, whereas bacterial and allergic conjunctivitis typically show a papillary reaction. Bacterial infections produce mucopurulent discharge; gonococcal infection produces thick yellow-green exudate. Preauricular lymphadenopathy is common in viral, HSV, gonococcal, and inclusion conjunctivitis. Trachoma leads to chronic follicular inflammation followed by scarring, entropion, trichiasis, and corneal damage. Parinaud oculoglandular syndrome, associated with Bartonella henselae, presents with granulomatous conjunctivitis and regional lymphadenopathy.
Diagnosis is usually clinical. Microbiologic testing is reserved for hyperacute, severe, chronic, or atypical cases. Gram stain may reveal gram-negative intracellular diplococci in gonococcal infection. Chlamydial infection may be diagnosed by Giemsa staining, culture, ELISA, immunofluorescence, or PCR. Viral pathogens can be identified by PCR. Imaging has no role in routine evaluation.
The differential diagnosis includes dry eye disease, allergic conjunctivitis, Stevens–Johnson syndrome, ocular cicatricial pemphigoid, drug-induced conjunctivitis, tumors, and graft-versus-host disease. In neonates, incubation time helps differentiate gonococcal (1–3 days) from chlamydial (5–14 days) conjunctivitis.
Treatment depends on etiology. Viral conjunctivitis generally requires supportive care with artificial tears and cold compresses. Topical steroids may be used cautiously for membranes or pseudomembranes, but are contraindicated in HSV infection, which requires topical antivirals such as trifluridine. Mild bacterial conjunctivitis is treated empirically with topical broad-spectrum antibiotics such as trimethoprim–polymyxin B or fluoroquinolones for 5–7 days. Haemophilus influenzae infections may require oral amoxicillin–clavulanate if systemic involvement is suspected.
Gonococcal conjunctivitis requires systemic ceftriaxone, with additional topical therapy and coverage for possible chlamydial coinfection using oral azithromycin. Adult inclusion conjunctivitis is treated with oral azithromycin and topical erythromycin or tetracycline ointment. Trachoma is treated with single-dose oral azithromycin and prolonged topical antibiotic therapy. Ophthalmia neonatorum requires systemic treatment based on the organism: ceftriaxone for gonococcal infection, oral erythromycin for chlamydial infection, and intravenous acyclovir for HSV infection.
Most cases of infectious conjunctivitis resolve within three weeks. Exceptions include untreated chlamydial infection, which may become chronic. Trachoma can lead to scarring, entropion, trichiasis, and corneal opacity, resulting in blindness. Viral EKC may cause subepithelial corneal infiltrates requiring prolonged steroid therapy. Neonates are at risk for systemic complications such as sepsis, meningitis, or pneumonia depending on the causative organism.
Preventive measures include hand hygiene, avoidance of sharing personal items, neonatal prophylactic ointment after birth, and treatment of sexual partners in chlamydial conjunctivitis. Public health interventions have significantly reduced the global burden of trachoma, though it remains an important cause of preventable blindness in endemic regions.
- Published on
Infectious Disease and Microbiology – Cryptosporidiosis
Cryptosporidiosis is caused by Cryptosporidium parvum and related species, including Cryptosporidium hominis and Cryptosporidium meleagridis. Cryptosporidium is an intracellular protozoan parasite that infects epithelial cells, primarily in the gastrointestinal tract. In immunocompetent individuals, infection typically causes self-limited watery diarrhea. However, in patients with advanced HIV infection or other forms of immunosuppression, it can lead to severe, protracted, and potentially life-threatening diarrhea.
Cryptosporidium is ubiquitous worldwide. In the United States, more than 300,000 cases occur annually. Seroprevalence rates reach up to 25% in industrialized countries and as high as 75% in developing regions. Transmission increases during warmer months in temperate climates. Large waterborne outbreaks have occurred, including the well-known outbreak in Milwaukee, Wisconsin, linked to contaminated municipal water. Contamination is often associated with agricultural runoff from dairy farms or other livestock operations. The organism is resistant to routine chlorination, making waterborne transmission particularly problematic.
Risk factors include advanced HIV infection (especially CD4 count <100 cells />mu;L), other immunosuppressive states, young children in developing countries, and animal handlers. Transmission occurs primarily through ingestion of oocysts in fecally contaminated water or food. Oocysts are highly resilient and may survive in the environment for up to 18 months. Ingestion of fewer than 1,000 oocysts can result in disease. Person-to-person transmission occurs in childcare centers, hospitals, through sexual contact, and via contaminated swimming pools. Transmission from pets and farm animals is also possible.
After ingestion, oocysts release sporozoites that infect epithelial cells of the small intestine. The parasite resides intracellularly but extracytoplasmically at the brush border of the mucosa. The entire life cycle occurs within a single host. Infection leads to impaired absorption, resulting in watery diarrhea and malabsorption. In immunocompromised patients, dissemination may occur, involving the biliary tree or respiratory tract.
The incubation period ranges from 7 to 10 days. In immunocompetent individuals, watery diarrhea lasts from several days up to one month and may be accompanied by crampy abdominal pain and low-grade fever. Vomiting is less common than with other causes of gastroenteritis. In patients with advanced immunosuppression, especially those with CD4 counts below 50 cells/μL, diarrhea may be profuse and exceed 10–15 liters per day. Weight loss, malnutrition, and recurrent disease occur in up to 40% of cases. Respiratory involvement may produce dyspnea.
Physical examination findings are nonspecific. In severe or chronic cases, signs of dehydration and wasting due to malabsorption may be evident.
Diagnosis is made by stool examination. Modified acid-fast staining demonstrates red or pink oocysts against a blue-green background. Immunofluorescent antibody staining is considered the gold standard. Enzyme-linked immunosorbent assays (ELISA), immunochromatographic tests, and PCR assays are also available and more sensitive than routine microscopy. Leukocytosis is uncommon, and fecal leukocytes or erythrocytes are typically absent. Malabsorption may result in abnormal D-xylose testing, elevated alkaline phosphatase levels, and low vitamin B12 levels. Imaging studies are nonspecific but may show ileus patterns or bowel wall edema. Biliary involvement may present with dilated intrahepatic or extrahepatic bile ducts, and respiratory involvement may show bilateral pulmonary infiltrates. Small intestinal biopsy reveals organisms attached to the brush border.
The differential diagnosis includes bacterial enteric infections such as Salmonella, Shigella, and Campylobacter; Clostridioides difficile infection; viral gastroenteritis; mycobacterial infections; other protozoal infections such as Giardia, Cyclospora, Isospora, and Microsporidia; and cytomegalovirus colitis.
Treatment depends on immune status. In immunocompetent individuals, the illness is typically self-limited and supportive care with hydration is sufficient. Nitazoxanide is effective in treating diarrhea in non-immunocompromised patients and is given for three days. In immunocompromised patients, especially those with AIDS, antiparasitic drugs have limited proven efficacy. Nitazoxanide has been used compassionately in such cases for extended durations. Paromomycin has shown variable results and may be combined with antimotility agents. Macrolides such as azithromycin and clarithromycin have some activity. Combination regimens (e.g., paromomycin plus azithromycin) and rifaximin have also been used.
Supportive care is critical, particularly in HIV-infected patients. Antimotility agents such as loperamide or diphenoxylate/atropine may help reduce stool frequency. Octreotide can decrease stool output without eradicating the organism. Immune reconstitution with effective antiretroviral therapy is the most important intervention in patients with AIDS and often leads to clinical improvement. Hospitalization and intravenous fluids are required for severely dehydrated patients, especially children.
Prognosis is generally good in immunocompetent individuals and in patients with HIV infection whose CD4 counts exceed 150 cells/μL. In advanced HIV infection, however, protracted diarrhea can be life-threatening. Complications include acalculous cholecystitis, sclerosing cholangitis, pancreatitis, tracheitis, and bronchitis when the respiratory tract is involved.
- Published on
Infectious Disease and Microbiology – Cryptococcal Infections
Cryptococcal infections are caused by encapsulated yeasts of the genus Cryptococcus. Although more than 50 species exist, the two most clinically important are Cryptococcus neoformans, which primarily affects immunocompromised individuals, and Cryptococcus gattii, which can also infect immunocompetent hosts. These organisms possess a thick polysaccharide capsule that is a major virulence factor. Infection occurs through inhalation of airborne yeast spores into the lungs. While pulmonary disease may remain localized, hematogenous dissemination can occur, particularly in patients with impaired cell-mediated immunity, with a strong predilection for the central nervous system (CNS). Other sites of dissemination include the skin, bones, prostate, and eyes.
In the United States, C. neoformans is more common and is associated with environments contaminated by pigeon droppings, although direct transmission from pigeons to humans has not been documented. C. gattii has traditionally been found in tropical and subtropical regions, particularly around eucalyptus trees, but has emerged in North America, especially in the Pacific Northwest and British Columbia. Respiratory transmission between humans has not been reported. Rare cases of human-to-human transmission have occurred through organ transplantation. Among individuals with HIV infection, the incidence of cryptococcal disease has declined significantly since the widespread use of antiretroviral therapy. In solid-organ transplant recipients, Cryptococcus is the third most common invasive fungal infection and accounts for a substantial proportion of cases in non-HIV patients.
Major risk factors for cryptococcal infection include AIDS (especially in patients with CD4 counts below 100 cells/μL), hematologic malignancies, solid-organ transplantation, and the use of immunosuppressive medications such as glucocorticoids, cyclosporine, and tacrolimus. Additional predisposing conditions include sarcoidosis, splenectomy, chronic obstructive pulmonary disease, diabetes mellitus, and autoimmune disorders such as lupus and rheumatoid arthritis.
After inhalation, yeast organisms deposit in the alveoli. In immunocompetent individuals, infection may remain localized or asymptomatic. In patients with impaired T-cell–mediated immunity, dissemination is more likely. Pulmonary infection represents primary disease, whereas meningitis, skin lesions, or involvement of other organs reflects disseminated infection. The organism’s tropism for the CNS results in cryptococcal meningitis, the most severe and common manifestation of disseminated disease.
Pulmonary cryptococcosis may range from asymptomatic infection to symptomatic pneumonia characterized by cough, dyspnea, fever, pleuritic chest pain, hemoptysis, and, rarely, acute respiratory distress syndrome. CNS infection typically presents with a subacute course over one to three weeks. Headache is the most common symptom and may be accompanied by fever, irritability, confusion, nausea, somnolence, and seizures. Only a minority of patients present with classic signs of meningitis such as neck stiffness and photophobia. On physical examination, nuchal rigidity is often absent. Papilledema is present in approximately one-third of patients due to elevated intracranial pressure. Skin involvement may manifest as painless papules, nodules, or ulcers, sometimes with central umbilication resembling molluscum contagiosum.
Diagnosis is established through laboratory and imaging studies. Serum cryptococcal antigen testing is highly sensitive and useful in both pulmonary and CNS disease. Blood cultures may grow Cryptococcus, particularly when fungal isolator tubes are used. In pulmonary disease, sputum culture or lung biopsy may be required. In CNS infection, cerebrospinal fluid (CSF) analysis is essential. Findings typically include elevated opening pressure (often >200 mm H₂O), elevated protein, low glucose, and lymphocytic pleocytosis. India ink staining may reveal encapsulated yeast, and CSF cryptococcal antigen testing is highly sensitive. Imaging studies such as chest radiography or CT may demonstrate interstitial infiltrates, nodules, cavitation, pleural effusions, lymphadenopathy, or cryptococcomas in pulmonary disease. Brain CT or MRI may reveal nodules, cryptococcomas, or hydrocephalus in CNS infection.
The differential diagnosis includes bacterial pneumonia, Pneumocystis pneumonia, tuberculosis, sarcoidosis, histoplasmosis, coccidioidomycosis, meningoencephalitis of other etiologies, and CNS metastases.
Treatment depends on the site and severity of disease. Mild-to-moderate pulmonary infection is treated with fluconazole 400 mg daily for 6–12 months. CNS infection requires an induction phase of amphotericin B (preferably a lipid formulation in patients at risk for nephrotoxicity) combined with flucytosine for at least 14 days. If there is clinical improvement, consolidation therapy with fluconazole 400 mg daily is given for eight weeks, followed by maintenance therapy with fluconazole 200 mg daily. In HIV-infected patients with prior cryptococcal meningitis, maintenance therapy is continued until immune reconstitution with sustained CD4 counts above 200 cells/μL for more than six months. Elevated intracranial pressure should be managed with serial lumbar punctures, and ventriculoperitoneal shunting may be required in refractory cases.
Complications of cryptococcal infection include persistent elevated intracranial pressure, hydrocephalus, visual impairment, cognitive decline, and death. Close monitoring of renal function during amphotericin and flucytosine therapy, and liver function during fluconazole therapy, is essential. Despite advances in antifungal therapy and HIV management, cryptococcal meningitis remains a major cause of morbidity and mortality worldwide.
- Published on
Emergency And Acute Medicine – Resuscitation, Neonate
Neonatal resuscitation addresses failure of the newborn to successfully transition from placental oxygenation to effective pulmonary respiration. Globally, nearly one million deaths annually are related to birth asphyxia. Approximately 10% of newborns require some assistance at birth, and about 1% require extensive resuscitation. In certain circumstances, resuscitation may be withheld after careful discussion with the family and care team, such as confirmed gestational age under 23 weeks, birth weight under 400 g, anencephaly, or confirmed trisomy 13 or 18. APGAR scores do not guide resuscitation and should not delay intervention. They are used to assess the infant’s response at 1 and 5 minutes but should never determine whether resuscitation is initiated.
The pathophysiology centers on hypoxia during the transition to extrauterine life. Initial hypoxia produces tachypnea followed by primary apnea, during which stimulation may restore breathing. Continued hypoxia results in secondary apnea, which does not respond to stimulation and requires assisted ventilation. Numerous antepartum and intrapartum risk factors increase the likelihood of resuscitation, including maternal hypertension, diabetes, infection, substance use, abnormal fetal heart tracings, emergency cesarean delivery, prematurity, meconium-stained amniotic fluid, and placental complications.
Compromised newborns may exhibit decreased muscle tone, inadequate respiratory effort, bradycardia, hypotension, cyanosis, or poor perfusion. Immediate assessment focuses on respirations, heart rate by auscultation or umbilical palpation, tone, and color. The essential first steps follow airway, breathing, and circulation principles while ensuring warmth. Heat loss is a significant risk, particularly in premature or low-birth-weight infants.
Initial stabilization includes warming, positioning the airway in a neutral “sniffing” position, clearing secretions if necessary, drying, and gentle stimulation. For term infants, room air is recommended initially to avoid hyperoxia. Premature infants may require blended oxygen with pulse oximetry monitoring. If apnea or heart rate less than 100 beats per minute persists after initial steps, positive-pressure ventilation is initiated at 40 to 60 breaths per minute using a properly fitting mask. Peak pressures may initially require 30 to 40 cm H₂O. If ventilation is prolonged, a nasogastric tube should be placed to reduce gastric distention.
If heart rate remains below 60 beats per minute after 30 seconds of effective ventilation, chest compressions are started using the two-thumb encircling technique or two-finger method. Compressions should depress the chest approximately one third of the anterior–posterior diameter. The compression-to-ventilation ratio is 3:1, achieving 120 events per minute (90 compressions and 30 breaths). If the heart rate remains below 60 beats per minute despite adequate ventilation and compressions, epinephrine should be administered via intravenous umbilical vein catheter or, if necessary, via the endotracheal tube.
Special situations require additional management. Nonvigorous infants with meconium-stained fluid may require endotracheal intubation and suctioning. Suspected hypovolemia warrants volume expansion with normal saline, lactated Ringer solution, or O-negative blood at 10 mL/kg. Hypoglycemia should be treated with intravenous dextrose. Severe metabolic acidosis may be addressed with sodium bicarbonate after ensuring adequate ventilation. Naloxone may be considered if maternal narcotic exposure occurred within four hours and the infant shows respiratory depression, but it is contraindicated in infants of opioid-dependent mothers due to risk of seizures. Persistent respiratory distress after resuscitation may indicate pneumothorax or congenital diaphragmatic hernia, the latter requiring immediate intubation and gastric decompression. Consider discontinuing resuscitation if there is persistent asystole after 10 minutes of adequate efforts.
Medication dosing includes epinephrine 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of 1:10,000 solution), dextrose 2 to 4 mL/kg of D10W, sodium bicarbonate 2 mEq/kg given slowly, naloxone 0.1 mg/kg, and volume expanders at 10 mL/kg. All medications are preferably administered via an umbilical venous catheter.
All newborns require hospital admission, and those requiring significant resuscitation should be admitted to a neonatal intensive care unit. Low-birth-weight and very-low-birth-weight infants are at risk for complications such as intraventricular hemorrhage, chronic lung disease, thermoregulatory instability, and retinopathy of prematurity. Excess oxygen exposure in very-low-birth-weight infants increases oxidative stress; therefore, careful titration of oxygen concentration is essential.
Successful neonatal resuscitation depends on anticipation of risk factors, preparation of equipment, rapid assessment, effective ventilation, and coordinated team response. Early and adequate ventilation remains the most critical intervention in preventing neonatal morbidity and mortality.
Neonatal resuscitation addresses failure of the newborn to successfully transition from placental oxygenation to effective pulmonary respiration. Globally, nearly one million deaths annually are related to birth asphyxia. Approximately 10% of newborns require some assistance at birth, and about 1% require extensive resuscitation. In certain circumstances, resuscitation may be withheld after careful discussion with the family and care team, such as confirmed gestational age under 23 weeks, birth weight under 400 g, anencephaly, or confirmed trisomy 13 or 18. APGAR scores do not guide resuscitation and should not delay intervention. They are used to assess the infant’s response at 1 and 5 minutes but should never determine whether resuscitation is initiated.
The pathophysiology centers on hypoxia during the transition to extrauterine life. Initial hypoxia produces tachypnea followed by primary apnea, during which stimulation may restore breathing. Continued hypoxia results in secondary apnea, which does not respond to stimulation and requires assisted ventilation. Numerous antepartum and intrapartum risk factors increase the likelihood of resuscitation, including maternal hypertension, diabetes, infection, substance use, abnormal fetal heart tracings, emergency cesarean delivery, prematurity, meconium-stained amniotic fluid, and placental complications.
Compromised newborns may exhibit decreased muscle tone, inadequate respiratory effort, bradycardia, hypotension, cyanosis, or poor perfusion. Immediate assessment focuses on respirations, heart rate by auscultation or umbilical palpation, tone, and color. The essential first steps follow airway, breathing, and circulation principles while ensuring warmth. Heat loss is a significant risk, particularly in premature or low-birth-weight infants.
Initial stabilization includes warming, positioning the airway in a neutral “sniffing” position, clearing secretions if necessary, drying, and gentle stimulation. For term infants, room air is recommended initially to avoid hyperoxia. Premature infants may require blended oxygen with pulse oximetry monitoring. If apnea or heart rate less than 100 beats per minute persists after initial steps, positive-pressure ventilation is initiated at 40 to 60 breaths per minute using a properly fitting mask. Peak pressures may initially require 30 to 40 cm H₂O. If ventilation is prolonged, a nasogastric tube should be placed to reduce gastric distention.
If heart rate remains below 60 beats per minute after 30 seconds of effective ventilation, chest compressions are started using the two-thumb encircling technique or two-finger method. Compressions should depress the chest approximately one third of the anterior–posterior diameter. The compression-to-ventilation ratio is 3:1, achieving 120 events per minute (90 compressions and 30 breaths). If the heart rate remains below 60 beats per minute despite adequate ventilation and compressions, epinephrine should be administered via intravenous umbilical vein catheter or, if necessary, via the endotracheal tube.
Special situations require additional management. Nonvigorous infants with meconium-stained fluid may require endotracheal intubation and suctioning. Suspected hypovolemia warrants volume expansion with normal saline, lactated Ringer solution, or O-negative blood at 10 mL/kg. Hypoglycemia should be treated with intravenous dextrose. Severe metabolic acidosis may be addressed with sodium bicarbonate after ensuring adequate ventilation. Naloxone may be considered if maternal narcotic exposure occurred within four hours and the infant shows respiratory depression, but it is contraindicated in infants of opioid-dependent mothers due to risk of seizures. Persistent respiratory distress after resuscitation may indicate pneumothorax or congenital diaphragmatic hernia, the latter requiring immediate intubation and gastric decompression. Consider discontinuing resuscitation if there is persistent asystole after 10 minutes of adequate efforts.
Medication dosing includes epinephrine 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of 1:10,000 solution), dextrose 2 to 4 mL/kg of D10W, sodium bicarbonate 2 mEq/kg given slowly, naloxone 0.1 mg/kg, and volume expanders at 10 mL/kg. All medications are preferably administered via an umbilical venous catheter.
All newborns require hospital admission, and those requiring significant resuscitation should be admitted to a neonatal intensive care unit. Low-birth-weight and very-low-birth-weight infants are at risk for complications such as intraventricular hemorrhage, chronic lung disease, thermoregulatory instability, and retinopathy of prematurity. Excess oxygen exposure in very-low-birth-weight infants increases oxidative stress; therefore, careful titration of oxygen concentration is essential.
Successful neonatal resuscitation depends on anticipation of risk factors, preparation of equipment, rapid assessment, effective ventilation, and coordinated team response. Early and adequate ventilation remains the most critical intervention in preventing neonatal morbidity and mortality.
- Published on
Emergency And Acute Medicine – Resuscitation, Neonate
Neonatal resuscitation addresses failure of the newborn to successfully transition from placental oxygenation to effective pulmonary respiration. Globally, nearly one million deaths annually are related to birth asphyxia. Approximately 10% of newborns require some assistance at birth, and about 1% require extensive resuscitation. In certain circumstances, resuscitation may be withheld after careful discussion with the family and care team, such as confirmed gestational age under 23 weeks, birth weight under 400 g, anencephaly, or confirmed trisomy 13 or 18. APGAR scores do not guide resuscitation and should not delay intervention. They are used to assess the infant’s response at 1 and 5 minutes but should never determine whether resuscitation is initiated.
The pathophysiology centers on hypoxia during the transition to extrauterine life. Initial hypoxia produces tachypnea followed by primary apnea, during which stimulation may restore breathing. Continued hypoxia results in secondary apnea, which does not respond to stimulation and requires assisted ventilation. Numerous antepartum and intrapartum risk factors increase the likelihood of resuscitation, including maternal hypertension, diabetes, infection, substance use, abnormal fetal heart tracings, emergency cesarean delivery, prematurity, meconium-stained amniotic fluid, and placental complications.
Compromised newborns may exhibit decreased muscle tone, inadequate respiratory effort, bradycardia, hypotension, cyanosis, or poor perfusion. Immediate assessment focuses on respirations, heart rate by auscultation or umbilical palpation, tone, and color. The essential first steps follow airway, breathing, and circulation principles while ensuring warmth. Heat loss is a significant risk, particularly in premature or low-birth-weight infants.
Initial stabilization includes warming, positioning the airway in a neutral “sniffing” position, clearing secretions if necessary, drying, and gentle stimulation. For term infants, room air is recommended initially to avoid hyperoxia. Premature infants may require blended oxygen with pulse oximetry monitoring. If apnea or heart rate less than 100 beats per minute persists after initial steps, positive-pressure ventilation is initiated at 40 to 60 breaths per minute using a properly fitting mask. Peak pressures may initially require 30 to 40 cm H₂O. If ventilation is prolonged, a nasogastric tube should be placed to reduce gastric distention.
If heart rate remains below 60 beats per minute after 30 seconds of effective ventilation, chest compressions are started using the two-thumb encircling technique or two-finger method. Compressions should depress the chest approximately one third of the anterior–posterior diameter. The compression-to-ventilation ratio is 3:1, achieving 120 events per minute (90 compressions and 30 breaths). If the heart rate remains below 60 beats per minute despite adequate ventilation and compressions, epinephrine should be administered via intravenous umbilical vein catheter or, if necessary, via the endotracheal tube.
Special situations require additional management. Nonvigorous infants with meconium-stained fluid may require endotracheal intubation and suctioning. Suspected hypovolemia warrants volume expansion with normal saline, lactated Ringer solution, or O-negative blood at 10 mL/kg. Hypoglycemia should be treated with intravenous dextrose. Severe metabolic acidosis may be addressed with sodium bicarbonate after ensuring adequate ventilation. Naloxone may be considered if maternal narcotic exposure occurred within four hours and the infant shows respiratory depression, but it is contraindicated in infants of opioid-dependent mothers due to risk of seizures. Persistent respiratory distress after resuscitation may indicate pneumothorax or congenital diaphragmatic hernia, the latter requiring immediate intubation and gastric decompression. Consider discontinuing resuscitation if there is persistent asystole after 10 minutes of adequate efforts.
Medication dosing includes epinephrine 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of 1:10,000 solution), dextrose 2 to 4 mL/kg of D10W, sodium bicarbonate 2 mEq/kg given slowly, naloxone 0.1 mg/kg, and volume expanders at 10 mL/kg. All medications are preferably administered via an umbilical venous catheter.
All newborns require hospital admission, and those requiring significant resuscitation should be admitted to a neonatal intensive care unit. Low-birth-weight and very-low-birth-weight infants are at risk for complications such as intraventricular hemorrhage, chronic lung disease, thermoregulatory instability, and retinopathy of prematurity. Excess oxygen exposure in very-low-birth-weight infants increases oxidative stress; therefore, careful titration of oxygen concentration is essential.
Successful neonatal resuscitation depends on anticipation of risk factors, preparation of equipment, rapid assessment, effective ventilation, and coordinated team response. Early and adequate ventilation remains the most critical intervention in preventing neonatal morbidity and mortality.
Neonatal resuscitation addresses failure of the newborn to successfully transition from placental oxygenation to effective pulmonary respiration. Globally, nearly one million deaths annually are related to birth asphyxia. Approximately 10% of newborns require some assistance at birth, and about 1% require extensive resuscitation. In certain circumstances, resuscitation may be withheld after careful discussion with the family and care team, such as confirmed gestational age under 23 weeks, birth weight under 400 g, anencephaly, or confirmed trisomy 13 or 18. APGAR scores do not guide resuscitation and should not delay intervention. They are used to assess the infant’s response at 1 and 5 minutes but should never determine whether resuscitation is initiated.
The pathophysiology centers on hypoxia during the transition to extrauterine life. Initial hypoxia produces tachypnea followed by primary apnea, during which stimulation may restore breathing. Continued hypoxia results in secondary apnea, which does not respond to stimulation and requires assisted ventilation. Numerous antepartum and intrapartum risk factors increase the likelihood of resuscitation, including maternal hypertension, diabetes, infection, substance use, abnormal fetal heart tracings, emergency cesarean delivery, prematurity, meconium-stained amniotic fluid, and placental complications.
Compromised newborns may exhibit decreased muscle tone, inadequate respiratory effort, bradycardia, hypotension, cyanosis, or poor perfusion. Immediate assessment focuses on respirations, heart rate by auscultation or umbilical palpation, tone, and color. The essential first steps follow airway, breathing, and circulation principles while ensuring warmth. Heat loss is a significant risk, particularly in premature or low-birth-weight infants.
Initial stabilization includes warming, positioning the airway in a neutral “sniffing” position, clearing secretions if necessary, drying, and gentle stimulation. For term infants, room air is recommended initially to avoid hyperoxia. Premature infants may require blended oxygen with pulse oximetry monitoring. If apnea or heart rate less than 100 beats per minute persists after initial steps, positive-pressure ventilation is initiated at 40 to 60 breaths per minute using a properly fitting mask. Peak pressures may initially require 30 to 40 cm H₂O. If ventilation is prolonged, a nasogastric tube should be placed to reduce gastric distention.
If heart rate remains below 60 beats per minute after 30 seconds of effective ventilation, chest compressions are started using the two-thumb encircling technique or two-finger method. Compressions should depress the chest approximately one third of the anterior–posterior diameter. The compression-to-ventilation ratio is 3:1, achieving 120 events per minute (90 compressions and 30 breaths). If the heart rate remains below 60 beats per minute despite adequate ventilation and compressions, epinephrine should be administered via intravenous umbilical vein catheter or, if necessary, via the endotracheal tube.
Special situations require additional management. Nonvigorous infants with meconium-stained fluid may require endotracheal intubation and suctioning. Suspected hypovolemia warrants volume expansion with normal saline, lactated Ringer solution, or O-negative blood at 10 mL/kg. Hypoglycemia should be treated with intravenous dextrose. Severe metabolic acidosis may be addressed with sodium bicarbonate after ensuring adequate ventilation. Naloxone may be considered if maternal narcotic exposure occurred within four hours and the infant shows respiratory depression, but it is contraindicated in infants of opioid-dependent mothers due to risk of seizures. Persistent respiratory distress after resuscitation may indicate pneumothorax or congenital diaphragmatic hernia, the latter requiring immediate intubation and gastric decompression. Consider discontinuing resuscitation if there is persistent asystole after 10 minutes of adequate efforts.
Medication dosing includes epinephrine 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of 1:10,000 solution), dextrose 2 to 4 mL/kg of D10W, sodium bicarbonate 2 mEq/kg given slowly, naloxone 0.1 mg/kg, and volume expanders at 10 mL/kg. All medications are preferably administered via an umbilical venous catheter.
All newborns require hospital admission, and those requiring significant resuscitation should be admitted to a neonatal intensive care unit. Low-birth-weight and very-low-birth-weight infants are at risk for complications such as intraventricular hemorrhage, chronic lung disease, thermoregulatory instability, and retinopathy of prematurity. Excess oxygen exposure in very-low-birth-weight infants increases oxidative stress; therefore, careful titration of oxygen concentration is essential.
Successful neonatal resuscitation depends on anticipation of risk factors, preparation of equipment, rapid assessment, effective ventilation, and coordinated team response. Early and adequate ventilation remains the most critical intervention in preventing neonatal morbidity and mortality.
